INTRODUCTION

Thyroid-associated ophthalmopathy (TAO) is an autoimmune disease and a common manifestation of Graves’ disease. In patients with moderate-to-severe and active TAO, treatment is required to relieve infiltrative eye changes and avoid further worsening. The major treatment options include corticosteroids, orbital radiotherapy and decompression surgery. Although there have been debates on whether radiotherapy is actually effective for TAO, radiotherapy has been recommended as an initial treatment for patients with moderate-to-severe TAO. Previous studies have shown that there is a good response to radiotherapy, with symptom improvement and stabilisation rates exceeding 90%. A total dose of 20 Gy in 10 fractions is generally suggested in the literature. Several retrospective studies and randomised controlled trials have compared treatment efficacy and toxicity among different dose fractionation schedules. However, these studies were limited by the small number of patients, and the endpoints for therapeutic responses were heterogeneous. Optimal fractionation schedules and recommended total doses remain unclear. To our knowledge, there has been no study that evaluated the efficacy of hypofractionated radiotherapy (fraction doses > 2 Gy) in patients with TAO. The purpose of this retrospective study was to assess the feasibility and efficacy of hypofractionated radiotherapy and the publication of early clinical results. This study was conducted to determine if a 1-week schedule of hypofractionated radiotherapy (20 Gy in five fractions) is as...
efficacious and safe as the standard 2-week schedule of conventional fractionated radiotherapy in patients with TAO.

METHODS

The records of all patients with TAO who received radiotherapy between September 2014 and March 2019 were analysed retrospectively. All patients were diagnosed with hyperthyroidism in the Department of Endocrinology and with TAO in the Department of Ophthalmology. The exclusion criteria were as follows: (i) patients who needed surgical treatment, such as orbital decompression; (ii) patients with active intraocular inflammation or infections; (iii) patients with uncontrolled diabetes; (iv) patients with prior retinopathy; and (v) patients younger than 30 years old.

During the patients’ first visit at the clinic, information regarding their smoking history, subjective symptoms, duration of Graves’ disease and TAO were collected. Visual acuity, intraocular pressure, slit lamp examination findings, exophthalmos status with Hertel exophthalmometry, and the presence of diplopia were evaluated at every visit. The severity of symptoms and disease was evaluated using the clinical activity score (CAS),12 NOSPECS (No physical signs or symptoms, Only signs, Soft tissue involvement, Proptosis, Extraocular muscle signs, Corneal involvement, and Sight loss) score.13 Hypertrophy of orbital fat and extraocular muscles and the associated functions were evaluated with CT, a Hess screen test, and a binocular single vision (BSV) test. In particular, the range of extraocular muscle motility and severity of diplopia were evaluated using the sum of the limitation scale size in four directions on the test chart outside the normal baseline in Hess screen test and the sum of the angle (degree) in eight directions of a non-diplopic region in a BSV test. Representative data of the patients in group II (in group II, 20 Gy was delivered in five fractions), including results of the Hess screen test and BSV test, CT scans, and nine cardinal gaze photographs, are shown in Figure 1(A-H).

All patients received three-dimensional conformal radiotherapy using a linear accelerator. CT scans with a slice thickness of 3 mm and without contrast were performed. The clinical target volume encompassing the bilateral retrobulbar tissues, including the extraocular muscle and retrobulbar fat, was delineated (Figure 2A). The treatment isocentre was placed behind the lens to half block the anterior divergence of the beam and minimise the dose to the lens. Opposed lateral 6 MV beams were used with wedges employed to maintain dose homogeneity within the target volume (Figure 2B). In group I, patients received a total dose of 20 Gy in 10 fractions over a 2-week period. In group II, the total dose of 20 Gy was delivered in five fractions of 4 Gy daily for five days in a 1-week period. The following organs at risk were delineated: lenses, eyeballs, optic nerves and lacrimal glands. The normal tissue constraints were as follows: lenses maximum dose <10 Gy; mean dose <3 Gy; eyeballs and optic nerves maximum dose <21 Gy; and lacrimal glands maximum dose <20 Gy. All patients underwent oral steroid therapy. The dose of oral steroids was 40–80 mg per day, administered in proportion to body weight; the dose was reduced by 10 mg per week in subsequent weeks. Three patients who had diabetes underwent oral steroid therapy after controlling their blood sugar levels. Oral steroids were given within 1 month after radiotherapy.

All patients were followed-up at 1-month post-radiotherapy and then every 1–3 months by an endocrinologist and ophthalmologist. One month after radiotherapy, the CAS was assessed and bilateral unilateral examinations were performed, and treatment efficacy and side-effects were evaluated.

Categorical variables were compared using the chi-square test. Continuous variables were compared using the Mann–Whitney test if the data did not have a normal distribution. A non-parametric Wilcoxon’s rank test was performed to assess the statistical significance of the differences between the two groups before and after radiotherapy. A p-value of less than 0.05 indicated statistical significance.

RESULTS

Twenty-eight patients (14 patients per group) were included in the analysis. The median follow-up periods of all patients, group

Figure 1. Clinical findings of thyroid ophthalmopathy patients (female, 51 aged) treated with radiotherapy in Group 2. (A, B, C) Hess screen test, binocular single vision (BSV) test, and CT before radiotherapy. (E, F, G) Hess screen test, BSV test, and CT of 2 months after radiotherapy. (D, H) Nine cardinal gaze photographs of patients, before and 2 months after radiotherapy. Extraocular muscle function movement and BSV had improved.
I, and group II were 19 months (range, 1–59 months), 36 months (range, 4–59 months), and 16 months (range, 1–35 months), respectively. Patient characteristics are shown in Table 1. The chief complaint of most patients was diplopia or exophthalmos.

In both groups, 11 patients complained of diplopia, and three patients in group I and two patients in group II complained of exophthalmos. Also, two patients in group I and three patients in group II complained of lid or periocular swelling. Radiotherapy

Table 1. Comparisons of patient characteristics between treatment groups

|                               | Group I (n = 14) | Group II (n = 14) | Total (n = 28) | p      |
|-------------------------------|-----------------|------------------|---------------|--------|
| Age (years)                   | 54.9 ± 13.2     | 59.0 ± 10.4      | 56.9 ± 11.9   | 0.511  |
| Sex                           |                 |                  |               | 1.000  |
| Male                          | 5 (35.7)        | 5 (35.7)         | 10 (35.7)     |        |
| Female                        | 9 (64.3)        | 9 (64.3)         | 18 (34.3)     |        |
| Smokers                       | 1 (7.1)         | 2 (14.3)         | 3 (10.7)      | 0.769  |
| Hypertension                  | 6 (42.9)        | 4 (28.6)         | 10 (35.7)     | 0.449  |
| Diabetic mellitus             | 1 (7.1)         | 3 (21.4)         | 4 (24.3)      | 0.297  |
| Axial length (mm)             | 23.79 ± 1.02    | 23.80 ± 1.20     | 23.79 ± 1.10  | 0.964  |
| Intraocular pressure (mmHg)   | 17.0 ± 5.4      | 17.7 ± 3.6       | 17.4 ± 4.6    | 0.582  |
| Duration of hyperthyroidism (years) | 1.1 ± 1.4   | 2.3 ± 3.5        | 1.7 ± 2.7     | 0.635  |
| Duration of TAO (months)      | 1.9 ± 3.0       | 2.5 ± 3.1        | 2.2 ± 3.0     | 0.642  |
| Thyroid hormone               |                 |                  |               |        |
| T3                            | 4 (28.6)        | 3 (21.4)         | 7 (25.0)      | 0.769  |
| Free T4                       | 3 (21.4)        | 3 (21.4)         | 6 (21.4)      | 1.000  |
| Thyroid antibody              |                 |                  |               |        |
| Thyroid stimulating antibody  | 13 (92.9)       | 13 (92.9)        | 26 (92.9)     | 1.000  |
| TSH receptor antibody         | 9 (64.3)        | 8 (57.1)         | 17 (60.7)     | 0.769  |
| Anti thyroid peroxidase antibody | 3 (21.4) | 7 (50.0)        | 10 (35.7)     | 0.21   |
| Thyroglobulin antibody         | 0 (0.0)         | 2 (14.3)         | 2 (7.1)       | 0.541  |

TAO, thyroid-associated ophthalmopathy; TSH, thyroid stimulating hormone
aData are presented as the means ± standard deviation or numbers with percentages in parentheses.
was initiated over a minimum period of 1 month to a maximum of 12 months after the onset of ocular inflammatory signs, with a median period of 1 month. There were no significant differences with respect to the variables considered between groups I and II.

The outcome measures that were assessed before and after radiotherapy are summarised in Table 2. For all patients in groups I and II, CAS and NOSPECS scores decreased significantly post-radiotherapy compared with pre-radiotherapy scores (p < 0.05), and the range of extraocular muscle motility in Hess screen test and BSV also improved significantly post-radiotherapy (p < 0.05). At least one NOSPECS parameter decreased in all 28 patients, and at least one CAS parameter decreased in 27 patients (96.4%). BSV improved in 20 patients (71.4%). There was no significant change in exophthalmos status pre- and post-radiotherapy. However, post-radiotherapy, there were no significant differences between groups I and II with respect to CAS, NOSPECS scores, the range of extraocular muscle motility in Hess screen test, or BSV improvement (p = 0.910, p = 0.769), respectively.

One patient in group I and two patients in group II experienced recurrence after radiotherapy. Twenty-five of the 28 patients did not experience recurrence or worsening of TAO after radiotherapy and required no further treatment for TAO during the follow-up period. Radiotherapy was well-tolerated, with no patient experiencing severe acute treatment reaction necessitating a treatment break. In addition, no radiation-related acute toxicity was observed, with the exception of bilateral periorbital redness observed in one group II patient. No late toxicity was observed in all patients during the follow-up period.

**DISCUSSION**

This retrospective study investigated the safety and effectiveness of hypofractionated radiotherapy in patients with TAO and compared the outcomes between standard fractionated radiotherapy (group I, 20 Gy in 10 fractions) and hypofractionated radiotherapy (group II, 20 Gy in five fractions). Statistically significant decreases in post-radiotherapy CAS and NOSPECS scores were observed in groups I and II. In both groups, the post-radiotherapy Hess screen test and BSV improved significantly compared with the pre-radiotherapy value. No statistically significant differences between groups I and II were observed for CAS, NOSPECS score, the range of extraocular muscle motility in Hess screen test, or BSV. The study results revealed that standard fractionated radiotherapy and hypofractionated radiotherapy are equally effective for patients with TAO.

Based on previous research, combined treatment with radiotherapy and corticosteroids should provide synergetic effects. Previous randomised controlled and retrospective studies showed that the combined treatment was more effective than either radiotherapy or corticosteroids alone.3,14–18 Combined treatment reduced the risk of compressive optic neuropathy17 and significantly lowered the recurrence rate of inflammation.14 Combined treatment can prevent the need for long-term use of corticosteroids and reduce the need for further invasive procedures, including orbital decompression. In this study, all patients were treated with combined radiotherapy and corticosteroids. All patients achieved a level of symptom palliation, and all but three patients experienced no recurrence throughout the follow-up period and did not require any further steroids or orbital decompression. The combination of radiotherapy and glucocorticoids may be an effective treatment for TAO.

The most commonly used radiotherapy dose and fractionation routine are a total dose of 20 Gy applied as 10 fractions of 2 Gy each.4,7,14,15,17,18 However, the optimal radiotherapy dose has not been sufficiently investigated. A total dose of 30 Gy did not improve outcome with respect to any of the ophthalmic parameters11; thus, a higher cumulative dose did not provide further benefits. Based on daily equivalent doses in terms of 2 Gy fractions, five fractions of 4 Gy (group II) resulted in a higher total dose than 10 fractions of 2 Gy (group I).19 Accordingly, the current study also found that no further benefits were obtained from a total dose of 20 Gy applied over five fractions compared to 20 Gy applied over 10 fractions. The rationale of using radiotherapy for TAO is to suppress the activated T lymphocytes and fibroblasts in the orbit. As these cells are very sensitive to radiation, lower doses of radiotherapy may be effective in suppressing them. A radiotherapy dose higher than 20 Gy applied over 10 fractions is not recommended. Therefore, it would be suggested

| Group I (n = 14) | Group II (n = 14) | pb | pb |
|------------------|------------------|----|----|
| Pre-treatment    | Post-treatment   | Pre-treatment | Post-treatment |
| CAS 3.4 ± 0.6    | 1.3 ± 0.8        | 0.001 | 3.7 ± 0.8 |
| NOSPECS 9.7 ± 2.5| 4.1 ± 1.5        | 0.001 | 10.9 ± 2.5 |
| Hess screen test | 3.1 ± 4.3        | 0.001 | 2.5 ± 6.1 |
| BSV (°) 172.1 ± 172.8 | 231.4 ± 193.9 | 0.008 | 180.7 ± 175.5 |
| Exophthalmometry (mm) 18.09 ± 2.63 | 18.05 ± 2.50 | 0.813 | 19.05 ± 31.12 |

CAS, clinical activity score; BSV, binocular single vision (°)
a-p-values were calculated using the Mann–Whitney test.
b-p-values were calculated using the Wilcoxon signed-rank test.
to reduce the fraction size to less than 4 Gy (i.e., fraction size of 3 Gy) when conducting five-fraction schedule of hypofractionated radiotherapy upon a TAO patient.

One study showed that the 1 Gy/week radiotherapy protocol (20 divided fractions of 1 Gy weekly over 20 weeks) was effective and tolerated in TAO patients. The longer treatment duration, however, makes this treatment schedule less practical and inconvenient for patients compared to standard fractionated radiotherapy. Two studies reported that delivering a small fraction of the lower total radiation dose yielded results similar to those obtained with the standard fractionation of 16–20 Gy in 8–10 fractions. One study showed that the total doses of 2.4 and 16 Gy in eight fractions were equally effective, and another reported that similar response rates were observed when the doses of 10 and 20 Gy in 10 fractions were used. One study found, however, that the vertical motility significantly improved in the group with 16 and 20 Gy irradiation than in the group with 12 Gy irradiation. A radiotherapy dose less than 12 Gy may be suboptimal for TAO patients. Thus, the dose of 16–20 Gy in 8–10 fractions is considered the optimal total dose for radiotherapy for TAO.

Conducting radiotherapy during the active phase is recommended because the ocular movement restriction progresses to fibrotic changes, which require surgical management. Once inflammatory infiltration has been replaced by fibrosis, radiotherapy may be effective in recent-onset TAO.

Several classification systems have been used for TAO to evaluate the disease severity and treatment efficacy. The CAS and NOSPECS classifications are commonly used in the evaluation of TAO, and some previous studies used the BSV test and Hess screen test to evaluate TAO. No method is both specific and completely reliable, and both the CAS and NOSPECS classifications have limitations in the evaluation of TAO. Therefore, in this study, we assessed the severity of the disease and the response using four methods (CAS, NOSPECS score, BSV test, and a Hess screen test) instead of only one or two. As a result, the patient’s symptoms were alleviated in all the four methods. The results of this study are thought to be reliable.

This study had a few limitations. First, it was a non-randomised retrospective study with a probability of unrecognised bias. Second, the study enrolled a small number of patients. Larger studies overcoming these limitations are needed in the future.

The results of this retrospective study suggest that, compared to standard fractionated radiotherapy, hypofractionated radiotherapy using a total dose of 20 Gy in five fractions does not provide significantly different outcomes with respect to efficacy or toxicity. Additional larger scale studies will be required to determine the efficacy of hypofractionated radiotherapy, and long-term follow up is needed to determine whether late-stage toxicity occurs post-treatment.

ACKNOWLEDGEMENTS
This research was supported by the Ministry of Health & Welfare, Republic of Korea (Grant/Award No. HI16C1559).

REFERENCES

1. Brent GA. Clinical practice. Graves’ disease. N Engl J Med 2008; 358: 2594–605.
2. Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med 2009; 360: 994–1001.
3. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56: 1139–44. doi: https://doi.org/10.1210/jcem-56-6-1139
4. Hahn E, Laperriere N, Millar B-A, Oestreicher J, McGowan H, Krema H, et al. Orbital radiation therapy for Graves’ ophthalmopathy: measuring clinical efficacy and impact. Pract Radiat Oncol 2014; 4: 233–9. doi: https://doi.org/10.1016/j.prro.2014.02.008
5. Johnson KTM, Wittig A, Loesch C, Eßer J, Sauerwein W, Eckstein AK. A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves’ orbitopathy. Græfes Arch Clin Exp Ophthalmol 2010; 248: 103–9. doi: https://doi.org/10.1007/s00417-009-1214-3
6. Marquez SD, Lum BL, McDougall IR, Katkuri S, Levin PS, MacManus M, et al. Long-Term results of irradiation for patients with progressive Graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys 2001; 51: 766–74. doi: https://doi.org/10.1016/S0360-3016(01)01699-6
7. Matthiesen C, Thompson JS, Thompson D, Farris B, Wilkes B, Ahmad S, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol
8. Prabhu RS, Liebman L, Wojno T, Hayek B, Hall WA, Crocker I. Clinical outcomes of radiotherapy as initial local therapy for Graves’ ophthalmopathy and predictors of the need for post-radiotherapy decompresive surgery. *Radiat Oncol* 2012; 7: 95. doi: https://doi.org/10.1186/1748-717X-7-95

9. Gerling J, Kommerell G, Henne K, Laubenberger J, Schulte-Mönting J, Fells P. Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy. *Int J Radiat Oncol Biol Phys* 2003; 55: 182–9. doi: https://doi.org/10.1016/S0360-3016(02)03795-1

10. Kahaly GJ, Rösler HP, Pirr S, Hommel G. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. *J Clin Endocrinol Metab* 2000; 85: 102–8. doi: https://doi.org/10.1210/jc.85.1.102

11. Petersen IA, Kriss JP, McDougall IR, Donaldson SS. Prognostic factors in the radiotherapy of Graves’ ophthalmopathy. *Int J Radiat Oncol Biol Phys* 1990; 19: 259–64. doi: https://doi.org/10.1016/0360-3016(90)90332-O

12. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. *Br J Ophthalmol* 1989; 73: 639–44. doi: https://doi.org/10.1136/bjo.73.8.639

13. Werner SC. Classification of the eye changes of Graves’ disease. *Am J Ophthalmol* 1969; 68: 646–8. doi: https://doi.org/10.1016/0002-9394(69)91246-X

14. Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS. Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy. *Graefes Arch Clin Exp Ophthalmol* 2016; 254: 991–8. doi: https://doi.org/10.1007/s00417-016-3280-7

15. Moracci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. *J Endocrinol Invest* 1991; 14: 853–60. doi: https://doi.org/10.1007/BF03347943

16. Ng CM, Yuen HKL, Choi KL, Chan MK, Yuen KT, Ng YW, CM N, YW N, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. *Hong Kong Med J* 2005; 11: 322–30.

17. Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. *Am J Ophthalmol* 2014; 157: 1299–305. doi: https://doi.org/10.1016/j.ajo.2014.02.044

18. Tsujino K, Hirota S, Hagiwara M, Fukada S, Takada Y, Hishikawa Y, et al. Clinical outcomes of orbital irradiation combined with or without systemic high-dose or pulsed corticosteroids for Graves’ orbitopathy. *Int J Radiat Oncol Biol Phys* 2000; 48: 857–64. doi: https://doi.org/10.1016/S0360-3016(00)00668-4

19. Joiner MC. A simple alpha/beta-independent method to derive fully isoeffective schedules following changes in dose per fraction. *Int J Radiat Oncol Biol Phys* 2004; 58: 871–5. doi: https://doi.org/10.1016/j.ijrobp.2003.10.036

20. Beckendorf V, Maalouf T, George JL, Bey P, Leclere J, Lupsori E. Place of radiotherapy in the treatment of Graves’ orbitopathy. *Int J Radiat Oncol Biol Phys* 1999; 43: 805–15. doi: https://doi.org/10.1016/S0360-3016(98)00405-2

21. Hurlíti T, Char DH, Harris J, Weaver K, Greenspan F, Sheline G. Radiation therapy for thyroid eye diseases. *Am J Ophthalmol* 1985; 99: 633–7. doi: https://doi.org/10.1016/0002-0315(85)90397-0

22. Choi SW, Lee JY, Lew H. Customized orbital decompression surgery combined with eyelid surgery or strabismus surgery in mild to moderate thyroid-associated orbitopathy. *Korean J Ophthalmol* 2016; 30: 1–9. doi: https://doi.org/10.3341/kjo.2016.30.1.1

23. Ben Simon GJ, Syed HM, Syed AM, Lee S, Wang DY, Schwarz RM, McCann JD, et al. Strabismus after deep lateral wall orbital decompression in thyroid-related orbitopathy patients using automated hess screen. *Ophthalmology* 2006; 113: 1650–5. doi: https://doi.org/10.1016/j.ophtha.2006.02.015

24. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ orbitopathy: systematic review and metaanalysis. *J Clin Endocrinol Metab* 2009; 94: 2708–16. doi: https://doi.org/10.1210/jc.2009-0376

25. Frueh BR. Why the NOSPECS classification of Graves’ eye disease should be abandoned, with suggestions for the characterization of this disease. *Thyroid* 1992; 2: 85–8. doi: https://doi.org/10.1089/thy.1992.2.85